Results 221 to 230 of about 56,913 (295)

Spotlight commentary: Addressing the persistent problem of benzodiazepine overuse, time for clinical, educational and AI‐driven reform

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3703-3706, November 2026.
Jakša Vukojević, Luka Horvat, Vito Papić, Andrija Štajduhar   +3 more
wiley   +1 more source

Contribution of cytochrome P450-mediated metabolism to clavulanic acid-induced cytotoxicity in TK6-derived cytochrome P450-overexpressing cell lines. [PDF]

Sci Rep
Fang JL, Li X, Chen S, Beland FA.
europepmc   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism. [PDF]

Biomedicines
Hirai T, Katayama K.
europepmc   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1195-1207, November 2026.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Pharmacokinetics and Safety Evaluation of the Transglutaminase 2 Inhibitor Suvigletistat in Healthy Chinese, Japanese, and White/European Participants. [PDF]

Clin Pharmacol Drug Dev
Nand RA, Woodcock H, Okrojek-Swiderek KA, Alvarez Y, Sharda M, Gupta A.   +5 more
europepmc   +1 more source

Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis

Hematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla   +9 more
wiley   +1 more source

Pharmacogenetic, Clinical, Prescribing, and Demographic Predictors of Sertraline Pharmacokinetics. [PDF]

Pharmaceutics
de la Cruz CG, Thomas L, Mata-Martín C, Villatoro-García JA, de Andrés F, González-Rodríguez I, González-Martínez I, Peñas-Lledó EM, LLerena A.   +8 more
europepmc   +1 more source

Plasma Interleukin‐10 Levels and IL10 Genetic Variants Are Associated With Clinical Outcomes in Patients With Severe COVID‐19 Treated With Corticosteroids

Journal of Medical Virology, Volume 98, Issue 11, November 2026.
ABSTRACT We aimed to evaluate the association between IL10 variants and plasma IL‐10 levels and clinical outcomes in patients with severe COVID‐19 treated with corticosteroids. We studied 944 patients with severe COVID‐19 who were treated with corticosteroids.
Ingrid Fricke‐Galindo, Francisco M. Ortega‐Villafuerte, Gloria Pérez‐Rubio, Ivette Buendía‐Roldán, Julián Ramírez‐Bello, Azael A. Castillo Morales, Leslie Chávez‐Galán, Rafael de Jesús Hernández‐Zenteno, Espiridión Ramos‐Martínez, Salvador García‐Carmona, Daniela Josefina Cataneo‐Piña, Nora Edith Bautista‐Félix, Ramcés Falfán‐Valencia   +12 more
wiley   +1 more source

Pharmacokinetic Drug-Drug Interactions of Imlunestrant in Healthy Female Participants of Nonchildbearing Potential. [PDF]

Clin Transl Sci
Datta-Mannan A, Shanks E, Yuen E, Cruz VR, Wang XA, Hall SD.   +5 more
europepmc   +1 more source